| Liu, Zimin |
KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension |
|
|
| Active, not recruiting | 3 | 120 | RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN® | Merck Sharp & Dohme LLC | Gastric Cancer, Gastroesophageal Junction Cancer | 02/24 | 04/25 | | |
NCT06730373: First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) |
|
|
| Recruiting | 2 | 110 | RoW | Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin, Capecitabine, 5-FU, Cisplatin | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma | 12/26 | 12/27 | | |
RCTS, NCT05586061: First-line Treatment With RC48 Plus Tislelizumab and S-1() in Advanced Gastric Cancer |
|
|
| Active, not recruiting | 2 | 55 | RoW | Disitamab vedotin, RC48, Tislelizumab, BGB-A317, S1 | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer | 12/24 | 12/24 | | |
NCT05585580: Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy |
|
|
| Recruiting | 2 | 59 | RoW | Serplulimab, Lenvatinib, Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome | Qilu Hospital of Shandong University | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | 11/25 | 11/26 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 12/25 | 12/25 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT04835324: Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study |
|
|
| Active, not recruiting | N/A | 650 | RoW | | Chinese Academy of Medical Sciences, Beijing Hospital, Jiangsu Cancer Institute & Hospital, The Affiliated Hospital of Qingdao University, Shanxi Province Cancer Hospital, Affiliated Hospital of Hebei University, Shandong Cancer Hospital and Institute, The First Affiliated Hospital of Zhengzhou University, Hebei Medical University Fourth Hospital, First Hospital of China Medical University | Advanced Colorectal Cancer | 02/22 | 10/22 | | |
NCT06157216: Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer |
|
|
| Active, not recruiting | N/A | 85 | RoW | MRD-guided therapy | Qilu Hospital of Shandong University, Shandong Provincial Hospital, Jinan Central Hospital, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University | Stage II-III Gastric Cancer | 04/27 | 04/29 | | |
NCT06609759: Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer |
|
|
| Recruiting | N/A | 197 | RoW | Standard chemotherapy regimen | Qilu Hospital of Shandong University, Shandong Provincial Hospital, Jinan Central Hospital, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University | Stage II-III Gastric Cancer | 01/28 | 01/29 | | |
| Recruiting | N/A | 190 | RoW | | Peking University Cancer Hospital & Institute | DMMR Cancer, MSI-H, Solid Tumor | 02/26 | 02/26 | | |
